Effect of Early Levodopa Treatment on Mortality in People with Parkinson's Disease

• Published in: Movement disorders clinical practice (Hoboken, N.J.) N.J.), 2024-10, Vol.11 (10), p.1249-1256
• Main Authors: Talebi, Amir H., Darweesh, Sirwan K.L., Bloem, Bas R., Bucur, Ioan G., Heskes, Tom
• Format: Article
• Language: English
• Subjects: claims database; deep brain stimulation; levodopa; Mortality; Parkinson disease; Parkinson's disease
• ISSN: 2330-1619; 2330-1619
• DOI: 10.1002/mdc3.14174

Background The ideal timing for initiating levodopa in newly diagnosed people with Parkinson's disease (PD) is uncertain due to limited data on the long‐term effects of levodopa. Objective The aim was to investigate whether early levodopa initiation postpones mortality (primary outcome), the requirement of device‐aided therapies, and the incidence of PD‐related complications, such as fall‐induced injuries. Methods Using nationwide claims data from Dutch hospitals (2012–2020), we grouped newly diagnosed PD individuals as “early initiators” (initiating levodopa within 2 years of diagnosis) or “nonearly initiators.” We used the national death registry to assess mortality and health‐care claims to assess PD‐related complications and device‐aided therapies. We used marginal structural models to compare mortality and device‐aided therapy rates between groups, and a Poisson regression model to compare PD‐related complication rates. Results Among 29,943 newly diagnosed PD individuals (mean age at diagnosis: 71.6, 38.5% female), there were 24,847 early and 5096 nonearly levodopa initiators. Over a median 4.25 years, 8109 (27.1%) died. The causal risk ratio for mortality was 1.04 (95% confidence interval [CI] 0.92–1.19) for early versus nonearly initiators. The risk ratio of receiving any device‐aided therapy was 3.19 (95% CI 2.56–5.80). No association was observed with incidence of PD‐related complications (incidence rate ratio: 1.00, 95% CI 0.96–1.05). Conclusions Early levodopa initiation in PD does neither postpone nor accelerate mortality or PD‐related complications, nor does it precipitate earlier occurrence of PD‐related complications or mortality. However, we cannot exclude that the results were influenced by residual confounding due to unmeasured risk factors of mortality.